

Anti-Spike RBD Antibody (Romlusevimab)

Introduction



Romlusevimab (BRII-198) is a neutralizing human IgG1 monoclonal antibody against the SARS-CoV-2 coronavirus spike protein.

Product parameters

| Alternative Names | BRII-198, BRII198 |
|----------------------------|---|
| Target Accession | |
| Target | Spike RBD |
| CAS number | 2509447-08-7 |
| Molecular Weight | 143.14 kDa |
| Host | СНО |
| Reactivity | Human |
| Co <mark>njug</mark> ation | Unconjugated () |
| Form Achieve Perfects | Liquid Achieve Perfection, Explore the Unknown |
| Concentration | See label |
| Buffer System | 100 mM Pro 20 mM Arg pH 5.0. No preservative! |
| Clonality | Monoclonal |
| Purification | - |
| Isotype | lgG1 |
| Application | ELISA, FACS, Kinetics, Functional assay, Animal Model |
| Biological activity | - |
| Endotoxin | Less than 0.1 EU/ug determined by LAL method. |
| Sterilization | 0.2 μM filtered |
| Reconstitution | For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration Gently shake it to solubilize the protein completely. Do not vortex. |
| Shipping | Dry ice O |
| Storage Storage | -80℃ |
| Expiration Date | 2 years |
| Note | Please avoid freeze-thaw cycles. |

Note

1. This product is for scientific research use only.









